Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $5.53 billion. The enterprise value is $6.39 billion.
| Market Cap | 5.53B |
| Enterprise Value | 6.39B |
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 45.54 million shares outstanding. The number of shares has decreased by -5.39% in one year.
| Current Share Class | 45.54M |
| Shares Outstanding | 45.54M |
| Shares Change (YoY) | -5.39% |
| Shares Change (QoQ) | +1.66% |
| Owned by Insiders (%) | 1.30% |
| Owned by Institutions (%) | 105.40% |
| Float | 44.93M |
Valuation Ratios
The trailing PE ratio is 54.21 and the forward PE ratio is 20.44. Haemonetics's PEG ratio is 1.82.
| PE Ratio | 54.21 |
| Forward PE | 20.44 |
| PS Ratio | 4.00 |
| Forward PS | 3.63 |
| PB Ratio | 6.23 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.53 |
| P/OCF Ratio | 16.02 |
| PEG Ratio | 1.82 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.55, with an EV/FCF ratio of 21.41.
| EV / Earnings | 61.46 |
| EV / Sales | 4.62 |
| EV / EBITDA | 17.55 |
| EV / EBIT | 24.53 |
| EV / FCF | 21.41 |
Financial Position
The company has a current ratio of 2.84, with a Debt / Equity ratio of 1.25.
| Current Ratio | 2.84 |
| Quick Ratio | 1.62 |
| Debt / Equity | 1.25 |
| Debt / EBITDA | 3.00 |
| Debt / FCF | 3.77 |
| Interest Coverage | 7.44 |
Financial Efficiency
Return on equity (ROE) is 11.89% and return on invested capital (ROIC) is 10.75%.
| Return on Equity (ROE) | 11.89% |
| Return on Assets (ROA) | 6.71% |
| Return on Invested Capital (ROIC) | 10.75% |
| Return on Capital Employed (ROCE) | 12.34% |
| Weighted Average Cost of Capital (WACC) | 6.60% |
| Revenue Per Employee | $459,441 |
| Profits Per Employee | $34,532 |
| Employee Count | 3,009 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.74 |
Taxes
In the past 12 months, Haemonetics has paid $38.10 million in taxes.
| Income Tax | 38.10M |
| Effective Tax Rate | 26.83% |
Stock Price Statistics
The stock price has increased by +65.11% in the last 52 weeks. The beta is 0.59, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +65.11% |
| 50-Day Moving Average | 113.68 |
| 200-Day Moving Average | 81.54 |
| Relative Strength Index (RSI) | 55.29 |
| Average Volume (20 Days) | 683,903 |
Short Selling Information
The latest short interest is 3.60 million, so 7.90% of the outstanding shares have been sold short.
| Short Interest | 3.60M |
| Short Previous Month | 3.04M |
| Short % of Shares Out | 7.90% |
| Short % of Float | 8.01% |
| Short Ratio (days to cover) | 5.01 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.38 billion and earned $103.91 million in profits. Earnings per share was $2.24.
| Revenue | 1.38B |
| Gross Profit | 826.20M |
| Operating Income | 260.39M |
| Pretax Income | 142.01M |
| Net Income | 103.91M |
| EBITDA | 363.87M |
| EBIT | 260.39M |
| Earnings Per Share (EPS) | $2.24 |
Balance Sheet
The company has $262.91 million in cash and $1.12 billion in debt, with a net cash position of -$860.85 million or -$18.90 per share.
| Cash & Cash Equivalents | 262.91M |
| Total Debt | 1.12B |
| Net Cash | -860.85M |
| Net Cash Per Share | -$18.90 |
| Equity (Book Value) | 898.50M |
| Book Value Per Share | 19.74 |
| Working Capital | 554.69M |
Cash Flow
In the last 12 months, operating cash flow was $344.93 million and capital expenditures -$46.69 million, giving a free cash flow of $298.24 million.
| Operating Cash Flow | 344.93M |
| Capital Expenditures | -46.69M |
| Depreciation & Amortization | 103.48M |
| Net Borrowing | -106.25M |
| Free Cash Flow | 298.24M |
| FCF Per Share | $6.55 |
Margins
Gross margin is 59.76%, with operating and profit margins of 18.84% and 7.52%.
| Gross Margin | 59.76% |
| Operating Margin | 18.84% |
| Pretax Margin | 10.27% |
| Profit Margin | 7.52% |
| EBITDA Margin | 26.32% |
| EBIT Margin | 18.84% |
| FCF Margin | 21.57% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 5.39% |
| Shareholder Yield | 5.39% |
| Earnings Yield | 1.84% |
| FCF Yield | 5.40% |
Analyst Forecast
The average price target for Haemonetics is $147.18, which is 21.30% higher than the current price. The consensus rating is "Buy".
| Price Target | $147.18 |
| Price Target Difference | 21.30% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 8.95% |
| EPS Growth Forecast (3Y) | 13.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 2.73 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.73 |
| Piotroski F-Score | 7 |